Last $47.87 USD
Change Today +0.22 / 0.46%
Volume 250.0K
PKI On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 12:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

perkinelmer inc (PKI) Snapshot

Open
$47.86
Previous Close
$47.65
Day High
$47.99
Day Low
$47.26
52 Week High
07/3/14 - $48.26
52 Week Low
07/23/13 - $33.60
Market Cap
5.4B
Average Volume 10 Days
574.9K
EPS TTM
$1.61
Shares Outstanding
113.2M
EX-Date
07/16/14
P/E TM
29.8x
Dividend
$0.28
Dividend Yield
0.59%
Current Stock Chart for PERKINELMER INC (PKI)

perkinelmer inc (PKI) Related Businessweek News

No Related Businessweek News Found

perkinelmer inc (PKI) Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerates the discovery and development of critical new therapies. This segment provides early detection for genetic disorders from pre-conception to early childhood, as well as offers digital x-ray flat panel detectors and infectious disease testing for the diagnostics market; and a suite of solutions, such as reagents, liquid handling, and detection and imaging technologies that enable researchers to improve the drug discovery process. Its research portfolio includes instrumentation for automation and detection solutions, in vitro and in vivo imaging and analysis hardware and software, and a portfolio of consumable products, including drug discovery and research reagents. The Environmental Health segment provides services and solutions to facilitate the creation of safer food and consumer products, secure surroundings, and efficient energy resources. This segment offers analytical technologies, solutions, and services that enable its customers to understand the health aspects of environment, including air, water, soil, and food; analytical instrumentation for the industrial market that comprise the chemical, petrochemical, lubricant, electronics, semiconductor, and quality assurance industries; and laboratory services. The company markets its products and services under various brands directly through its own sales force. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

7,583 Employees
Last Reported Date: 05/6/14
Founded in 1931

perkinelmer inc (PKI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $978.3K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $469.6K
President of Human Health
Total Annual Compensation: $341.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $430.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2013.

perkinelmer inc (PKI) Key Developments

PerkinElmer Launches Two New Automated Electrophoresis Systems

PerkinElmer Inc. has launched the new LabChip GX Touch and GXII Touch automated electrophoresis systems. The LabChip platform's key feature is automation of conventional gel electrophoresis, eliminating the need for manual sample preparation. The LabChip GX Touch and GXII Touch benefit customers by reducing hands-on time and simplifying data generation via a user friendly operator touch screen. The LabChip platform provides the data and throughput necessary to perform effective nucleic acid quantification and protein characterization. The LabChip GX system can enhance genomics research process by precisely quantifying nucleic acids. The GXII Touch system helps to accelerate the development of biotherapeutic drugs by automating the protein characterization process. The LabChip GXII Touch system's rapid reporting of multiple protein critical quality attributes can support customer needs throughout the product life cycle. The LabChip Touch platform's top differentiator is its ability to perform electrophoresis in microfluidic channels. The LabChip GX Touch system provides rapid, quantifiable data for pre and post-PCR sample analysis, which is critical for next-generation sequencing and genomics workflows. The LabChip GXII Touch system quantifies protein attributes from process development through quality control in biotherapeutics development and manufacturing.

PerkinElmer, Inc. Launches New EnSight Multimode Plate Reader

PerkinElmer Inc. has launched new EnSight multimode plate reader. The EnSight system is the first plate reader on the market to offer both labeled and label-free detection, together with well-imaging technology (which facilitates cell imaging), on a single benchtop system. This unique combination allows researchers to run their assays on the same platform - generating more predictive results earlier in the drug discovery process. Scientists can use the EnSight system for their research into cancer, cytotoxicity, biotherapeutics, epigenetics and primary/stem cells. The EnSight system enables researchers to generate more reliable readouts and obtain an expanded set of data from their samples. They can also use the EnSight system's variety of technology modes to perform confirmatory assays, helping to ensure that results are not biased to the detection technologies used for their sampling. The EnSight system offers cell imaging capabilities that allow researchers to quickly visualize cells and generate per-cell data. When using primary/stem cells, this per-cell data is a more physiologically relevant model than the per-well data generated by traditional multimode detection technologies. In addition to the unique combination of detection technologies it offers, the EnSight system also benefits from PerkinElmer's new Kaleido Data Acquisition and Analysis Software. This software's workflow-based interface enables researchers to quickly and easily set up and run assays, perform analysis tasks (such as cell counting), and generate graphs and reports. Alongside cell imaging capabilities, the EnSight system also offers Alpha Technology (a bead-based proximity assay technology platform), as well as PerkinElmer's LANCEand DELFIATRF assay platforms. The system also features Epic Label-free Technology, which provides rich, physiologically relevant information about cellular and biochemical systems, without label interference.

Enzo Biochem Announces Settlement Agreement with PerkinElmer

Enzo Biochem, Inc. along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer, Inc. has agreed to pay $7,000,000 in escrow in settlement pursuant to the Agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PKI:US $47.87 USD +0.22

PKI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Getinge AB kr166.00 SEK +2.00
MEDNAX Inc $57.82 USD -0.13
QIAGEN NV €18.52 EUR +0.05
Sirona Dental Systems Inc $81.57 USD +0.05
Teleflex Inc $106.88 USD +0.60
View Industry Companies
 

Industry Analysis

PKI

Industry Average

Valuation PKI Industry Range
Price/Earnings 31.8x
Price/Sales 2.4x
Price/Book 2.7x
Price/Cash Flow 31.9x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERKINELMER INC, please visit www.perkinelmer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.